Axsome Therapeutics AXSM Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's net change in cash?
- Axsome Therapeutics (AXSM) reported net change in cash of -$17.83M in Q1 2026.
- How has Axsome Therapeutics's net change in cash changed year-over-year?
- Axsome Therapeutics's net change in cash decreased by 23.4% year-over-year, from -$14.44M to -$17.83M.
- What does net change in cash mean?
- The total change in the company's cash balance over the period.
- How do you interpret net change in cash?
- An increase indicates positive net cash flow, while a decrease suggests cash burn or significant capital deployment.
- How does net change in cash compare across companies?
- Standard across all industries; biopharma companies often show negative values during intensive R&D phases.